RoX's Investment Forum

[cleverrox]

Assessed MFLU ($0.94) and did not buy. I would be interested in getting into it around $0.80 a share. I may place an open order for it. They look to have at least a little growth potential and it will be interesting to see if they can keep increasing gross margins. They have done so the last three quarters. It seems to me they may have squeezed a lot of the easy waste out of their system already.

From 10bagger post:

MFLU..$0.89

This IMO is one cheap stock..hank

Microfluidics International Corporation Announces Third Quarter 2009 Financial Results

Company Reports Net Income, Strong Demand by Vaccine Developers and Manufacturers

NEWTON, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU - News), today reported unaudited financial results for the third quarter ended September 30, 2009.

Third quarter accomplishments:

•Earned net income for the third quarter of $425,000
•Achieved $650,000 in earnings before interest, taxes, depreciation and amortization (EBITDA)
•Delivered strong bookings in the third quarter of $4.8 million and a backlog of $4.75 million as of September 30, 2009
•Generated $4.5 million in revenue for the third quarter, a 27% increase over the same period in 2008

"I am pleased to report that the strategic plan we implemented a year ago has led us to our first profitable quarter since my joining the Company," said Michael C. Ferrara, Chief Executive Officer of Microfluidics. "We will continue to innovate with new products, increase international representative and distributor coverage, streamline costs and improve quality in support of our customers as we strive to carry this positive momentum through the second half of the year and into 2010."

"The initiatives and strong cost controls implemented in the first half of the year are yielding tangible results," said Peter Byczko, Vice President of Finance and Chief Accounting Officer. "Demand in our product line remains strong, especially within our core biopharmaceutical markets and customers are exhibiting increased interest in value-added services as they realize the importance of maximizing machine uptime and availability. We are pleased with our results and will continue to work to improve the financial position of the Company."

Third Quarter Financial Results:

Revenues for the three months ended September 30, 2009 were $4.5 million, an increase of $1.0 million, or 27%, as compared to revenues of $3.5 million for the three months ended September 30, 2008. North American revenues were $3.2 million, an increase of 63% as compared to $2.0 million in the third quarter of 2008. The increase in North America was offset by a 19% decrease in foreign sales from $1.5 million for the third quarter of 2008 to $1.3 million for the third quarter of 2009. Our gross margin increased to 66% in the third quarter of 2009. This increase is attributable to pricing actions taking effect and appropriately adjusting our pricing to cover additional services requested by our customers. Net income was $425,000, or $0.04 per diluted share, for the three months ended September 30, 2009 as compared to a net loss of $1.1 million, or $0.10 per diluted share, for the same period in 2008.

EBITDA was $650,000 for the three months ended September 30, 2009 compared with a $930,000 EBITDA loss for the same period in 2008. EBITDA is a Non-GAAP financial measure. A reconciliation of GAAP net income to Non-GAAP EBITDA is provided in the financial tables that accompany this release and is discussed under the section below titled "Non-GAAP Financial Measures."

Year to Date Financial Results:

Revenues for the nine months ended September 30, 2009 were $11.5 million, an increase of $83,000, or 1%, as compared to revenues of $11.4 million for the nine months ended September 30, 2008. Net loss was $442,000, or $0.04 per diluted share, for the nine months ended September 30, 2009 as compared to $2.3 million net loss, or $0.22 per diluted share, for the same period in 2008.

EBITDA was $230,000 for the nine months ended September 30, 2009 compared with $2.1 million EBITDA loss for the same period in 2008.
http://investorshub.advfn.com/boards/board.aspx?board_id=10347
http://investorshub.advfn.com/boards/board.aspx?board_id=5211
http://investorshub.advfn.com/boards/board.aspx?board_id=3251